title: Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation.
abstract: We retrospectively evaluated the efficacy of bortezomib in 23 patients with multiple myeloma who had relapsed after allografting. Bortezomib was given as single agent to 9 patients (39%) and in combination with steroids in the other 14 (61%). Major toxicities were thrombocytopenia (10/23, 43%) and peripheral neuropathy (12/23, 52%). The overall response rate was 61% (14/23), including 22% (5/23) immunofixation-negative complete remissions. No significant differences in toxicity and response rates were seen between patients treated with bortezomib plus steroids and bortezomib alone. After a median follow-up of 6 months, progression free survival was 6 months. Twenty-one patients are alive, two and five in continuous very good partial and complete remissions, respectively.
authors.affiliation: Division of Hematology, Azienda Ospedaliera San Giovanni Battista, University of Torino, Torino, Italy. benedetto.bruno@unito.it
authors.forename: Benedetto
authors.initials: B
authors.lastname: Bruno
authors.forename: Francesca
authors.initials: F
authors.lastname: Patriarca
authors.forename: Roberto
authors.initials: R
authors.lastname: Sorasio
authors.forename: Daniele
authors.initials: D
authors.lastname: Mattei
authors.forename: Vittorio
authors.initials: V
authors.lastname: Montefusco
authors.forename: Jacopo
authors.initials: J
authors.lastname: Peccatori
authors.forename: Francesca
authors.initials: F
authors.lastname: Bonifazi
authors.forename: Maria Teresa
authors.initials: MT
authors.lastname: Petrucci
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Milone
authors.forename: Stefano
authors.initials: S
authors.lastname: Guidi
authors.forename: Luisa
authors.initials: L
authors.lastname: Giaccone
authors.forename: Marcello
authors.initials: M
authors.lastname: Rotta
authors.forename: Renato
authors.initials: R
authors.lastname: Fanin
authors.forename: Mario
authors.initials: M
authors.lastname: Boccadoro
authors.forename: Paolo
authors.initials: P
authors.lastname: Corradini
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D003907:Dexamethasone / Q000627:therapeutic use*; D018572:Disease-Free Survival; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy / Q000628:therapy*; D011719:Pyrazines / Q000627:therapeutic use*; D012008:Recurrence; D012189:Retrospective Studies; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone